In Vitro Diagnostics Firms Frustrated By FDA Delays

Sidebar: In Vitro Diagnostics (IVD) industry -- more information Manufacturers of devices that test fluids or tissues outside the body say the agency's excessively high standard hinders innovation. Photo: Feit's Photography MAJOR BLOW: National Medical Device Coalition’s Wayne Barlow says delays in FDA approval devastate small companies. The in vitro diagnostics (IVD) industry has long been frustrated by lengthy delays in the United States Food and Drug Administration (FDA) product-appr

Written byRobert Finn
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Sidebar: In Vitro Diagnostics (IVD) industry -- more information

IVDs include all devices that test body fluids or tissues to detect, diagnose, and manage medical conditions. They range from the automated clinical chemistry analyzers used in hospitals to simple home pregnancy tests. According to the Washington, D.C.-based Health Industry Manufacturers Association (HIMA), in 1995 the total value of the U.S. IVD industry's products was $8.9 billion.

Regulation of the industry began with the passage of the 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act. In this legislation, IVDs were lumped together with implantable devices such as cardiac pacemakers. The categorization has been a cause of consternation for industry ever since.

"In vitro diagnostics are products that are used outside the body," explains Carolyn Jones, HIMA's director of technology and regulatory affairs. "From our perspective, they don't pose the same risk as an implantable device. But FDA ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies